Guang Dong First Condor Biotechnology

Guangdong First Condor Biotechnology is a clinical-stage biopharmaceutical company headquartered in China, specializing in the development of next-generation cell therapies for oncology and regenerative medicine. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and CAR-NK cell therapies, with a diverse pipeline targeting both hematological malignancies and difficult-to-treat solid tumors such as liver and gastric cancers. First Condor operates integrated R&D centers and large-scale GMP manufacturing facilities to support its clinical programs and commercialization strategy. Their technological innovations include universal CAR-T (UCAR-T) platforms and multi-target cell therapies designed to overcome the immunosuppressive microenvironment of solid tumors. Additionally, the company maintains a significant presence in the stem cell industry through its specialized cell banking and research services.